Performances Evaluation of New FibroScan Probes Dedicated to Morbidly

Status Completed

Clinical Trial Summary

Non-Alcoholic Fatty Liver is a common clinical and histological condition associated with metabolic syndrome in patients with and without excess body weight. It represents the most common cause of liver disease in the western world and it is characterized by an excess accumulation of fatty vacuole within hepatocytes. Patients with non-alcoholic fatty liver disease (NAFLD) can progress to non-alcoholic steatohepatitis (NASH), and then into cirrhosis and its complications. The prevalence of hepatic steatosis goes from 16 to 31% in the general population, from 50 to 80% in the obese population and up to 96% in morbidly obese patients. As the majority of obese individuals have NAFLD, non-invasive and widely applicable screening tools for the assessment of liver fibrosis and steatosis are needed. The detection in early stages is the main predictive factor of the long-term outcome. Liver biopsy has traditionally been the gold standard for the assessment of patients with NAFLD, although the well-known limitations. Among the non-invasive tools available in the market, the FibroScan® (Echosens™, Paris, France) has been shown to be a useful tool for diagnosing fibrosis and steatosis in patients with suspected NAFLD. The FibroScan® is an ultrasound-based vibration-controlled transient elastography (VCTE™) device dedicated to liver stiffness measurement (LSM) and the controlled attenuation parameter (CAP). Several clinical studies have shown the benefit of measuring hepatic stiffness with the FibroScan® in overweight/moderately obese persons. The ability to identify significant fibrosis and cirrhosis has been demonstrated in normal and overweight patients affected with chronic hepatitis B and C, biliary diseases, alcohol related liver disease and NAFLD. However, subcutaneous fat attenuates the transmission of shear waves into the liver and the ultrasonic signals used to measure their speed of propagation. When scanning morbidly obese patients (BMI≥35 kg/m²) with the XL+ probe, unreliable results occur mainly due to obesity. Therefore, the XL probe has been enabled to expand the applicability of the FibroScan® but, the realization of the XL+ examination is still very difficult in the case of morbidly obese patients. This is why to reduce this failure rate, Echosens has worked on developing the XXL probe specifically for measuring the LSM in morbidly obese patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03872024
Study type	Interventional
Source	Echosens
Contact
Status	Completed
Phase	N/A
Start date	September 19, 2019
Completion date	March 24, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04517591` - Reducing Sedentary Time in Bariatric: The Take a STAND for Health Study	N/A
Active, not recruiting	`NCT04583683` - Effects of Very Low Calorie Diet vs Metabolic Surgery on Weight Loss and Obesity Comorbidities	N/A
Completed	`NCT01550601` - Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity	N/A
Completed	`NCT03638843` - Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy - Part 2	N/A
Recruiting	`NCT05917795` - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates	N/A
Completed	`NCT03339791` - Sleeve Versus Bypass in Older Patients: a Randomized Controlled Trial	N/A
Recruiting	`NCT05711758` - Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure
Not yet recruiting	`NCT04209842` - Effectiveness Gastric Balloon in Obese Adolescents	N/A
Recruiting	`NCT03100292` - Korean OBEsity Surgical Treatment Study	N/A
Active, not recruiting	`NCT04357119` - Common Limb Length in One-anastomosis Gastric Bypass	N/A
Completed	`NCT03210207` - Gastric Plication in Mexican Patients	N/A
Completed	`NCT02590406` - EPO2-A: Evaluation of Pre-Oxygenation in Morbid Obesity: Effect of Position and Positive Pressure Ventilation	N/A
Completed	`NCT01840020` - BAR-trial: Bioavailability of Ethanol Following Bariatric Surgery
Completed	`NCT01183975` - Swedish Adjustable Gastric Banding Observational Cohort Study	N/A
Terminated	`NCT05993169` - Body Composition Optimization Intervention RCT	N/A
Not yet recruiting	`NCT05974995` - Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer	N/A
Recruiting	`NCT05554016` - The UFO (Ultra Processed Foods in Obesity) Project
Completed	`NCT05519423` - Investigation of the Effectiveness of Whatsapp-Based Physical Activity Incentive Program in Morbidly Obese Individuals	N/A
Not yet recruiting	`NCT05499949` - The Franciscus Obesity NASH Study
Completed	`NCT05502120` - A Comparison of Vie-Scope and Macintosh Blade Laryngoscopes in Morbidly Obese.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms